Agilent director files notice to sell 634 shares

AGILENT TECHNOLOGIES, INC.

Rhea-AI Filing Summary

AGILENT TECHNOLOGIES, INC. (A) reports that director Mikael Dolsten has filed a notice to sell 634 shares of the company’s common stock, with an aggregate market value of $95,971.75, through Fidelity Brokerage Services LLC on the NYSE on September 4, 2026.

The shares derive from restricted stock vesting on March 19, 2026 that was issued as compensation by the company.

Key Figures

Shares to be sold: 634 shares Aggregate market value: $95,971.75 CUSIP: 281928854 +3 more

6 metrics

Shares to be sold 634 shares Common stock covered by the Rule 144 notice

Aggregate market value $95,971.75 Total market value of 634 shares proposed for sale

CUSIP 281928854 CUSIP for Agilent Technologies, Inc. common stock

Planned sale date September 4, 2026 Date of proposed sale on the NYSE

Acquisition date March 19, 2026 Date the shares vested as restricted stock compensation

Issuer phone number (408) 345-8886 Contact phone number for Agilent Technologies, Inc.

Key Terms

Rule 144, Restricted Stock Vesting, attorney-in-fact

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Vesting financial

"Common | 03/19/2026 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

attorney-in-fact regulatory

"as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

What did Agilent Technologies, Inc. (A) disclose in this Form 144 filing?

Agilent Technologies, Inc. disclosed that director Mikael Dolsten filed a notice under Rule 144 to sell 634 shares of Agilent common stock through Fidelity Brokerage Services LLC on the NYSE on September 4, 2026.

How many Agilent (A) shares are covered by Mikael Dolsten’s planned Rule 144 sale?

The planned Rule 144 sale covers 634 shares of Agilent Technologies, Inc. common stock, as reported in the securities information section of the notice.

What is the aggregate market value of the Agilent (A) shares in this Form 144?

The notice reports an aggregate market value of $95,971.75 for the 634 shares of Agilent Technologies, Inc. common stock proposed to be sold.

When were the Agilent (A) shares to be sold by Mikael Dolsten acquired?

The shares were acquired on March 19, 2026 through restricted stock vesting provided by Agilent Technologies, Inc. as compensation.

On which exchange are the Agilent (A) shares in this Form 144 expected to be sold?

The filing states that the 634 shares of Agilent Technologies, Inc. common stock are expected to be sold on the NYSE.

Who is acting on behalf of Mikael Dolsten in the Agilent (A) Form 144 filing?

The notice is signed by Joshua Schmitt as a duly authorized representative of Fidelity Brokerage Services LLC, acting as attorney-in-fact for G. M. Dolsten.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/04/2026 - 04:19 PM Accepted by SEC EDGAR 09/04/2026 - 04:19 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001437590
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	AGILENT TECHNOLOGIES, INC.
SEC File Number	001-15405
Address of Issuer	5301 STEVENS CREEK BLVD SANTA CLARA CALIFORNIA 95051
Phone	(408) 345-8886
Name of Person for Whose Account the Securities are To Be Sold	Dolsten Mikael
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	634	95971.75	281928854	09/04/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	03/19/2026	Restricted Stock Vesting	Issuer			634	03/19/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/04/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Joshua Schmitt, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for G. M. Dolsten.
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)